Based upon the evidence, leflunomide and consequently teriflunomide are candidates for personalized dosing for use in RA. The small unbound fraction of teriflunomide within the blood makes ...

[20] In a 36-week Phase II study of relapsing MS, teriflunomide-treated patients showed a statistically significant decrease in active MRI lesions, and fewer subjects receiving high-dose ...

Merck said that ARR for oral teriflunomide was lower than has been seen in other recent phase 3 trials, which made it harder for evobrutinib to show an advantage, but that will be small comfort to ...